Authorship note: smh and fa contributed equally to this work. mjaw and cw are co-senior authors. conflict of interest: mjg and mjaw are cofounders and equity holders in pepgen, a company developing peptide-conjugated oligonucleotides. cw, mb, gt, and ig are employed by astrazeneca

HIGHLIGHTS

• who: Antibody-oligonucleotide conjugate and colleagues from the DepartmentUniversity of of Molecular Biology, Cambridge, United Kingdom have published the research: Authorship note: SMH and FA contributed equally to this work. MJAW and CW are co-senior authors. Conflict of interest: MJG and MJAW are cofounders and equity holders in PepGen, a company developing peptide-conjugated oligonucleotides. CW, MB, GT, and IG are employed by AstraZeneca, in the Journal: (JOURNAL) of August/18,/2021
• what: The authors report that systemic delivery of PMOs directly conjugated to the anti-mouse TfR monoclonal antibody 8D3130 yields even greater . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.